|
Glaxo, Theravance report Relovair safety data
BusinessWeek GlaxoSmithKline PLC and Theravance Inc. said Wednesday their lung disease and asthma drug Relovair met its goals in a mid-stage safety study. … GSK and Theravance announce combination ICS/LABA Phase II results in the … GlaxoSmithKline Reports Positive Results For Phase II Trial Of Relovair In … Theravance Announces Results From Phase II Study For Developmental Combination … |
View full post on asthma – Google News